Phosphorus binders and survival on hemodialysis. - Wikidata - awgldk - TriplyDB

Phosphorus binders and survival on hemodialysis.

Phosphorus binders and survival on hemodialysis.

http://www.wikidata.org/entity/Q34907022

about

Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease Phosphate control in end-stage renal disease: barriers and opportunities Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence Hyperparathyroidism of Renal Disease Lanthanum carbonate: safety data after 10 years Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.Phosphate and cardiovascular disease Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4 Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients.Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients.Diagnosis and management of mineral metabolism in CKD.A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum.Calcium Overload Accelerates Phosphate-Induced Vascular Calcification Via Pit-1, but not the Calcium-Sensing Receptor Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis.Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients Pharmacology, efficacy and safety of oral phosphate binders.Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.Klotho deficiency causes vascular calcification in chronic kidney disease.Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.Prescribed dietary phosphate restriction and survival among hemodialysis patients.Tip-toeing toward the finish line.Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells.

P2860

Q26786000-FA1A98D8-A3C9-460F-BBA2-303301AD7FF1 Q26830013-01B652CA-3DB3-471C-BF7C-4752BA0E0DCB Q26849298-7D351237-F323-4493-AB2B-1E7647371D14 Q26853372-6D88FA62-8B8B-4E98-82C6-3BBD267822A5 Q27011288-F0AC2F9F-0F36-4E62-BC46-8EFA8400FFA5 Q27013882-807DFF02-99CE-46EF-B5BC-E7A8A1AC81CD Q28068593-B29F3041-615D-46DC-B249-46F6271036FC Q28079982-475EDB10-583E-4D64-90E6-B0014F1A7D93 Q30427104-8BD8C1D1-FAE6-40C8-B96B-31541629EFDC Q30429870-91DB0B68-4836-4F15-990F-485DE978BA22 Q30544587-843BEF14-7F88-479F-B6FC-D34F59E003A2 Q33510868-991A1B0D-D23A-45A8-A68F-B58325921CC1 Q33566596-FF4E7DC3-689C-4F12-B5B8-6047148DB924 Q33610457-FFBEE664-0E07-4A69-B3C1-6BDE095B9E48 Q33715785-D17A4599-F453-4E98-A780-B052CDFF4ADC Q33736093-C17B142B-B5ED-467D-83E4-0F55CD57322C Q33749467-3ED79F5D-48DD-46A7-9E3A-B6D4B3B4C0DD Q33769983-2B01D0F5-4835-4CF6-90B1-39C5768250AB Q33801022-C4CBBD95-2E82-4CA8-9D1C-E4FF21E6AC09 Q33821566-108A8442-490A-4ECD-91DD-0B68D09BB462 Q33890218-9F8F9B51-618D-4833-8839-7FECE0EF350B Q33898681-E47182EC-54C6-49FA-AAF2-F776FC1F985F Q33916132-F2121983-1347-454F-8192-663D130E1D4C Q33918759-B5211337-848F-4680-B292-CDC36813760C Q34004393-10F6261C-990A-4A29-8A67-7E63BB398B3D Q34027316-12863841-5C86-4EFF-AC00-800A4ED5EF41 Q34116591-9B16F7F7-A5EF-4250-A789-AEEDB65E62CB Q34213752-C9509C3A-662F-4A96-AE57-3F4B08D8CFC2 Q34254746-0AEA05CF-BAD5-495C-9F00-D6EF807DBCE2 Q34403555-2E7A05D4-87FB-498D-AEDA-BA46FFA07722 Q34406863-F17B11BE-9277-4A0D-86FD-0DED4EC47092 Q34457281-F4D3F6F2-A590-4D9A-92B4-57AFDCE975FB Q34463433-B2A7FE33-C23A-4822-A4BB-4BDCB88B5F82 Q34497220-4B6D085A-965A-4AE8-A22E-A3859BE22AD7 Q34573734-FFC841E7-7742-4B77-9527-4557D378D378 Q34858005-52F0445C-A6EC-40AD-B496-43ABCF8427A1 Q34865383-FD161A35-3DD7-456A-B0A5-3CE2428FBDEF Q35007369-5F74385F-870E-4447-8B80-FF41C8CC01A3 Q35030613-B799B0A2-1CBE-42E3-9F5E-71CD0BD00C96 Q35107539-058469E6-61C1-4AEA-98EB-50563AF6D475

P2860

Phosphorus binders and survival on hemodialysis.

http://www.wikidata.org/entity/Q34907022

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phosphorus binders and survival on hemodialysis.

@ast

Phosphorus binders and survival on hemodialysis.

@en

Phosphorus binders and survival on hemodialysis.

@nl

type

label

Phosphorus binders and survival on hemodialysis.

@ast

Phosphorus binders and survival on hemodialysis.

@en

Phosphorus binders and survival on hemodialysis.

@nl

prefLabel

Phosphorus binders and survival on hemodialysis.

@ast

Phosphorus binders and survival on hemodialysis.

@en

Phosphorus binders and survival on hemodialysis.

@nl

P1433

Q34907022-3CCA746E-94F2-420F-ABF9-F64C94AA3751

P1476

Q34907022-24585293-96DB-451C-B539-E3A14331AD95

P2093

Q34907022-0D65071C-5EB9-4570-9737-44D28C1C373E

Q34907022-103A9578-94BF-4956-8E4E-D01177DCF1FF

Q34907022-60E816CE-D681-4554-B205-B41CA217A1B6

Q34907022-69515CB3-0968-4AF4-9E32-CB0B749CB942

Q34907022-873E18CD-BD3A-4D39-A67F-AECB4EB40ABA

Q34907022-A68C0F97-2CE2-4DD6-93D3-C183C1A45037

Q34907022-C46AFED4-9828-4B36-9A8F-49D3BB3EEB4D

Q34907022-C55C66ED-AEDA-488D-A596-1E5C576C279D

P2860

Q34907022-0DEBF4E5-2849-477F-8298-4E2E3CC29152

Q34907022-14053DA2-399C-4026-AF7B-1207BB24ACD1

Q34907022-194CA276-182F-4A0A-AC48-73BE9AD164DC

Q34907022-19AD1D24-C1F5-43E8-AB15-C13286057B95

Q34907022-35A2E9F8-3D5A-4A11-977B-9F2C2E352385

Q34907022-3E4478D9-ABC0-4835-8B11-8CB08305C36E

Q34907022-4EC0F56B-36F2-4B0E-B491-35491E1F2890

Q34907022-510787C6-9A05-4B74-B3C8-046D907E00B1

Q34907022-518BC88C-294F-4F0B-9226-FA680C512AAA

Q34907022-5B288B1F-0583-4BD7-84B9-EA7254E8B6C2

P304

Q34907022-CE3CC1A1-FE28-499A-AC33-BF8FD710F94D

P31

Q34907022-9AFECD28-AF6A-4E5E-BE7C-C3534E253F76

P356

Q34907022-5BC71937-0290-429C-936C-F29662CA0C80

P433

Q34907022-338CEB85-B035-462F-89D4-6B94F29070CB

P478

Q34907022-8FD65ABF-A541-47E2-91C8-D2BFE99CF0B5

P577

Q34907022-C0D83A99-468B-4877-9629-8D76B59F18CC

P5875

Q34907022-B217CFEC-6139-4089-AC10-8B9ECD185E98

P698

Q34907022-DCA2EE27-21FF-472D-9037-4740B9222745

P932

Q34907022-5BA31984-87D5-451D-99D6-8737048D385D

P356

P1433

Journal of the American Society of Nephrology

P1476

Phosphorus binders and survival on hemodialysis.

@en

P2093

Anand Shah

http://www.w3.org/2001/XMLSchema#string

Hector Tamez

http://www.w3.org/2001/XMLSchema#string

Kelsey Smith

http://www.w3.org/2001/XMLSchema#string

Myles Wolf

http://www.w3.org/2001/XMLSchema#string

Orlando M Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Ravi Thadhani

http://www.w3.org/2001/XMLSchema#string

Tamara Isakova

http://www.w3.org/2001/XMLSchema#string

Yuchiao Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Prevalence of chronic kidney disease in the United States

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Public health approach to addressing hyperphosphatemia among dialysis patients.

The mechanism of phosphorus as a cardiovascular risk factor in CKD

Statin use and sepsis events [corrected] in patients with chronic kidney disease.

P304

388-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2008060609

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23673166

http://www.w3.org/2001/XMLSchema#string

P698

19092121

http://www.w3.org/2001/XMLSchema#string

P932

2637053

http://www.w3.org/2001/XMLSchema#string